ResearchAndMarkets.com added a new report on the ataxia telangiectasia market that tracks epidemiology, treatment patterns, reimbursement, competition, and pipeline development across the seven major markets from 2020 to 2034. The study says diagnosis may improve as disease awareness rises, clinical recognition happens earlier, ATM genetic testing advances, and rare disease surveillance strengthens. It describes ataxia telangiectasia as a rare autosomal recessive disorder (condition requiring two faulty gene copies) caused by pathogenic ATM gene mutations and notes that no disease-modifying therapies have been approved specifically for the condition. Secondary analysis in the report estimates that about 1% of the U.S. population carries an ATM gene mutation, while prevalence is about one in 150,000 in Europe and one in 100,000 in Japan. The current care model remains supportive, using measures such as immunoglobulin replacement, antioxidants, amantadine, baclofen, physical therapy, and occupational therapy rather than treatments that halt progression. The pipeline focus includes Quince Therapeutics' EryDex, also known as eDSP, and IntraBio's IB1001, or N-acetyl-L-leucine. As of June 2025, Quince Therapeutics said its Phase III NEAT trial had passed 75% enrollment with 65 of 86 planned participants randomized, and the company aims to file a New Drug Application with the US Food and Drug Administration (U.S. drug regulator) in the second half of 2026 if results are favorable. The report says possible launches between 2025 and 2034 could broaden the treatment landscape and support market growth, with the United States accounting for a significant share of the seven-market opportunity in 2024.